Novartis Ag

Sanofi

Dana-farber-cancer Institute Inc.

Chonghui Zhang

Jennifer Brogdon

Lu Huang

Tony Fleming

Connie Hong

Aida Abujoub

John Blankenship

Brian Holmberg

Dexiu Bu

Daniel J Tavares

Igor Splawski

Michel Streuli

John Trauger

Veronique Blanc

Fabienne Parker

Claudia Fromond

William Dole

Kurt Alex Heldwein

Jiawen Han

Xiao-Mai Zhou

Min Li

Joshua Goldstein

Glenn Dranoff

Stuart F Schlossman

Boris Engels

Brian Walter Granda

Carla Guimaraes

Michael R Greene

Xu Zhu

Elizabeth Dorothy Pratico

Louise Treanor

Andrew Price

Joni Waiee Lam

Anniesha Hack

Serena De Vita

Hyungwook Lim

Olja Kodrasi

Attilio Bondanza

Akash Sohoni

Andrew Marc Stein

Véronique Blanc

Min Immunogen Inc Li

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

BCMA chimeric antigen receptors and uses thereof

The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as 'LOX-1'), and pharmaceutical compositions and methods of treatment comprising the same.

Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies

Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.

EPHA2 receptor antagonist antibodies

Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies

Lectin-like oxidized LDL receptor 1 antibodies and methods of use

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

Methods of use for antibodies that specifically bind to the EphA2 receptor

A monoclonal antibody which specifically binds to an antigen on the membrane of mitochondria in apoptotic cells. The antigen is a 38 kD protein that is detectable in cells undergoing apoptosis and undetectable in normal cells. This selectivity of the monoclonal antibody provides a method of distinguishing between normal and apoptotic cells in a sample of human hemopoietic cell populations. A method for detecting and measuring cells undergoing apoptosis is also provided.

Monoclonal antibody that detects apoptotic antigen

Growing community of inventors

Brookline, MA, United States of America

Chonghui Zhang